Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 3/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.50 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30046308 | 0.86 | NPC1 (0.59) | SMN1; SMN2CYP2C19KMT2AMEN1MAPT | |
| SCHEMBL18974104 | 0.86 | NPC1 (0.59) | SMN1; SMN2CYP2C19KMT2AMEN1MAPT | |
| SCHEMBL18974108 | 0.86 | KMT2A (0.56) | SMN1; SMN2KMT2AMEN1MAPTRAB9A | |
| SCHEMBL11479178 | 0.84 | GAA (0.51) | SMN1; SMN2MAPTRAB9ANPC1GAA | |
| SCHEMBL1222782 | 0.84 | SMN1; SMN2 (0.57) | SMN1; SMN2MAPTRAB9ANPC1GAA | |
| SCHEMBL24073601 | 0.82 | HDAC3 (0.58) | SMN1; SMN2KMT2AMEN1MAPTPOLB | |
| SCHEMBL29470218 | 0.82 | PDCD1 (0.51) | GAAALDH1A1 | |
| SCHEMBL18987060 | 0.82 | PDCD1 (0.51) | GAAALDH1A1 | |
| SCHEMBL24931248 | 0.82 | SMN1; SMN2 (0.89) | SMN1; SMN2CYP2C19KMT2AMEN1MAPT | |
| SCHEMBL321802 | 0.81 | GAA (0.64) | SMN1; SMN2KMT2AMEN1RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219939-A1 | N-(1-CYANO-PYRROLIDIN-3-YL)-5-(3-(TRIFLUOROMETHYL)PHENYL)OXAZOLE-2-CARBOXAMIDE DERIVATIVES AND THE CORRESPONDING OXADIAZOLE DERIVATIVES AS USP30 INHIBITORS FOR THE TREATMENT OF MITOCHONDRIAL DYSFUNCTION | MISSION THERAPEUTICS LIMITED (GB) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219939-A1 | N-(1-CYANO-PYRROLIDIN-3-YL)-5-(3-(TRIFLUOROMETHYL)PHENYL)OXAZOLE-2-CARBOXAMIDE DERIVATIVES AND THE CORRESPONDING OXADIAZOLE DERIVATIVES AS USP30 INHIBITORS FOR THE TREATMENT OF MITOCHONDRIAL DYSFUNCTION | USP30, UQCRC1, NDUFAF1 | SMN1; SMN2 2324/4885CYP2C19 3996/4885KMT2A 3440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.